

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AUG 0 9 2002

TECH CENTER 1600/2900

Group Art Unit: 1624

Examiner:

In re the application of: Jiri Zemlicka et al.

Serial No.: 10/047202

Filed: January 14, 2002

For: 2-HYDROXYMETHYLCYCLOPROPYL-IDENEMETHYLPURINES, AND -PYRIMIDINES AS

ANTIVIRAL AGENTS >

Attorney Docket No.: WSV-374CPCN

Commissioner for Patents Washington, D.C. 20231

## Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents. Washington. D.C. 20231 on the date set forth below.

Date of Signature and of Mail Deposit

By:

DeAnn F. Smith, Esq. Registration No. 36,683

**Attorney for Applicants** 

## INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following publications and information, listed on the attached PTO Form 1449, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

The present application is a Continuation Application of U.S. Serial No. 09/267839, filed March 12, 1999 (Atty. Docket No. WSV-374CP), which is now U.S. Patent 6,352,991. The majority of the references listed on the enclosed PTO Form 1449 have been previously cited by or submitted to the Office in the prior application, and, in accordance with 37 CFR §1.98(d), copies of references A1, A3-A15, B1-B3, B5-B11

Group Art Unit: 1624

are not enclosed, but will be provided upon request. The remaining references A2 and B4 have not been previously cited and are enclosed herewith.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publications.

Under 37 CFR § 1.97(b)(3), no additional costs are believed to be due in connection with the filing of this disclosure. If, however, a first Office Action on the merits issues in this application bearing a mailing date prior to the date of this Information Disclosure Statement, please charge the appropriate fee as required under 37 CFR §1.17(p) to our Deposit Order Account No. 12-0080.

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

DeAnn F. Smith, Esq. Registration No. 36,683 Attorney for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

Date: August 1, 2002

DFS/TRW/alf Enclosures



COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
Ic@lahive.com

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V. SMURZYNSKI RALPH A. LOREN GIULIO A. DeCONTI, JR. ANN LAMPORT HAMMITTE ELIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J CANNING JANE E. REMILLARD Deann FORAN SMITH PETER C. LAURO JEANNE M. DIGIORGIO DEBRA J. MILASINCIC, Ph.D. DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER

CYNTHIA L. KANIK, Ph.D.
MEGAN E. WILLIAMS, Ph.D.
RICHA NAND
MICHAEL PHILLIPPS \*
LISA M. DIROCCO
HATHAWAY P. RUSSELL \*\*
MARIA LACCOTRIPE ZACHARAKIS, Ph.D
PETER A. DIMATTIA
VINCENT P. LOCCISANO
MERIDETH C. ARNOLD

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
WILLIAM A. SCOFIELD, JR.
SIBLEY P. REPPERT

PATENT AGENTS
THEODORE R. WEST
SHAYNE Y. HUFF, Ph.D.
DANIEL B. KO

TECHNICAL SPECIALISTS
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.
EUIHOON LEE
JENNIFER K. ROSENFIELD
ALLAN TAMESHTIT, Ph.D.
CATHERINE E. McPHERSON
ERIC F. WAGNER, Ph.D.
SHAHID HASAN, Ph.D.
JACOB G. WEINTRAUB
JONATHAN M. SPARKS, Ph.D.
CRISTIN E. HOWLEY, Ph.D.

\* Admitted in NY only

## RECEIVED

August 1, 2002

AUG 0 9 2002

TECH CENTER 1600/2900

Commissioner for Patents Washington, D.C. 20231

Re:

.....

U.S. Patent Application No.: 10/047202

For: 2-HYDROXYMETHYLCYCLOPROPYLIDENEMETHYLPURINES

AND -PYRIMIDINES AS ANTIVIRAL AGENTS

Inventors: Jiri Zemlicka et al. Filed: January 14, 2002

Our Ref. No.: WSV-374CPCN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Information Disclosure Statement;
- 2. PTO Form 1449;
- 3. Copies of selected references cited in PTO Form 1449 (2); and
- 4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on:

DeAnn F. Smith, Esq., Reg. No. 36,683

Respectfully submitted,
LAHIVE & COCKFIELD, LLP

DeAnn F. Smith, Esq. Registration No. 36,683 Attorney for Applicants